Chicago Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Chicago Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.46M	Buy	17,029 +4,910	+41%	+$2.18M	0.2%	71
2026 Q1	$5.41M	Sell	12,119 -26	-0.2%	-$12.1K	0.15%	81
2025 Q4	$5.51M	Sell	12,145 -679	-5%	-$293K	0.14%	85
2025 Q3	$5.02M	Sell	12,824 -51	-0.4%	-$21.3K	0.12%	87
2025 Q2	$5.73M	Buy	12,875 +469	+4%	+$216K	0.14%	77
2025 Q1	$6.01M	Buy	12,406 +188	+2%	+$87.6K	0.17%	80
2024 Q4	$4.92M	Sell	12,218 -74	-0.6%	-$34.3K	0.13%	85
2024 Q3	$5.72M	Sell	12,292 -377	-3%	-$181K	0.16%	78
2024 Q2	$5.94M	Buy	12,669 +282	+2%	+$122K	0.18%	78
2024 Q1	$5.18M	Buy	12,387 +447	+4%	+$189K	0.16%	76
2023 Q4	$4.86M	Buy	+11,940	New	+$4.41M	0.17%	75

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Chicago Capital's VRTX Position: Q2 2026 in Review

Chicago Capital increased its Vertex Pharmaceuticals (VRTX) stake by 41% in Q2 2026, buying an estimated $2.18M and bringing the position to 17,029 shares worth $8.46M. The position accounts for 0.2% of the portfolio, ranked #71.

Chicago Capital first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Chicago Capital held 17,029 shares of Vertex Pharmaceuticals worth $8.46M as of Q2 2026.
Chicago Capital bought 4,910 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.18M.
Vertex Pharmaceuticals made up 0.2% of Chicago Capital's portfolio in Q2 2026, its #71 holding.
Chicago Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Chicago Capital's 13F filing for Q2 2026, filed 28 Jul 2026.